India’s Biologics Aspirations Face Challenges from China
Indian companies aiming to capitalize on the global biologics market are facing significant challenges as China’s dominance in biotech supply chains intensifies. Recent reports indicate that Chinese firms have secured over half of the latest project deals from U.S. biotech companies, highlighting the difficulties Indian players encounter in entering the complex biologics sector. Unlike the generics market, where India has thrived due to cost efficiency, biologics require advanced research and development, sophisticated manufacturing, and specialized talent, creating higher barriers to entry and increased financial risks.
China’s Rising Biotech Influence
In recent years, China has rapidly established itself as a formidable player in the biotech industry. In 2023, biologics accounted for approximately 42% of new drug approvals in China, a significant increase from just 9% in 2015. This growth underscores China’s strengthening position in global supply chains for complex biologics. K V Subramaniam, president of Reliance Life Sciences, noted that China’s government policies, expedited regulatory approvals, and the resolution of a substantial drug approval backlog have propelled its biopharmaceutical sector ahead of India. As a result, Indian companies must reassess their strategies to gain a foothold in advanced therapies.
Challenges for Indian Biotech Firms
The competitive landscape for Indian biotech firms is becoming increasingly daunting. Analysts, including Tausif Shaikh from BNP Paribas, emphasize that Chinese companies have demonstrated unmatched operational scale, cost competitiveness, and established capabilities. Recent project flows indicate that these firms have secured more than half of their new orders from U.S. biotech companies, further complicating the prospects for Indian players. The market research firm IQVIA estimates that 118 biologics will lose patent protection in the U.S. between 2025 and 2034, representing a potential global biosimilar market worth approximately $232 billion. While India’s biosimilar exports currently stand at around $0.8 billion, projections suggest they could grow five-fold to $4.2 billion by 2030 and potentially reach $30–35 billion by 2047.
The Future of India’s Biosimilars Industry
Leaders in the Indian biosimilars sector recognize the pivotal moment their industry is facing. Shreehas Tambe, CEO and Managing Director of Biocon, remarked that the early years of India’s biosimilars industry were characterized by cost efficiency, establishing the country as a reliable producer of high-quality generic medicines. However, the next phase will require a shift from cost leadership to capability leadership. Experts like Suresh Subramanian, national life sciences leader at EY-Parthenon India, stress that while India possesses broad capabilities, it must address critical gaps. These include enhancing cell line engineering, improving legal and intellectual property frameworks, and boosting market access in the U.S. Additionally, Indian firms need to scale up manufacturing for newer modalities, such as those emerging from hybrid sciences like cell and gene therapies.
Strategic Recalibration Needed
As the global biologics landscape evolves, Indian companies must recalibrate their strategies to remain competitive. The challenges posed by China’s advancements in biotech are significant, but they also present an opportunity for Indian firms to innovate and strengthen their capabilities. By focusing on research and development, enhancing manufacturing processes, and addressing market access issues, Indian players can carve out a meaningful share in the burgeoning global biosimilars market. The future of India’s biosimilars industry will depend on its ability to adapt and respond to these challenges while leveraging its existing strengths in the pharmaceutical sector.
Observer Voice is the one stop site for National, International news, Sports, Editor’s Choice, Art/culture contents, Quotes and much more. We also cover historical contents. Historical contents includes World History, Indian History, and what happened today. The website also covers Entertainment across the India and World.
Follow Us on Twitter, Instagram, Facebook, & LinkedIn
